trial

A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

NCTId NCT00261430
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 650 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
650 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
—
Primary completion
—
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
GAIN Acceptance Approach

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
650
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
GAIN Acceptance Approach
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication